Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 343 participants.

Also called NCT01603082

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 343 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01603082
Other papers using this trial's data
  • Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI Journal of the American College of Cardiology, 2016-02-16 DOI, PubMed 26868683

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01603082. Randomized; no masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2014-06 (actual). Results posted on 2015-12-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
Condition
Acute Coronary Syndrome
Intervention (Drug)
Ticagrelor
Intervention (Drug)
Clopidogrel
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct01603082
Content hash
e93d79e2ae182cbd972b27c892aa3d32f7f5d41634481ef64431f2fa7797c38e